Todos Medical announced distribution agreement with Adial Pharma to market Assure/FaStep Covid-19 antibody tests
On Oct. 22, 2020, Todos Medical announced that it had entered into an exclusive supply agreement with U.S….
-
-
FDA approved first treatment for COVID-19
On Oct. 22, 2020, the FDA approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric…
-
Landmark study 31/A5349 on the treatment of drug-susceptible TB
On Oct. 22, 2020, the World Health Organizationﾒs Global TB Programme welcomed the results from a landmark study…
-
Landmark TB trial identified shorter-course treatment regimen
On Oct. 21, 2020, results from an international, randomized, controlled clinical trial indicated that a four-month daily treatment…
-
ImmunityBio, NantKwest announced first patient dosed in phase 1 clinical trial of second-generation COVID-19 vaccine candidate
On Oct. 21, 2020, ImmunityBio and NantKwest announced that the first patient had been dosed in the Phase…
-
Merck announced positive topline results from phase 3 adult studies evaluating V114 15-valent pneumococcal conjugate vaccine
On Oct. 20, 2020, Merck announced findings from two additional Phase 3 studies evaluating the safety, tolerability and…
-
Final report confirmed remdesivir benefits for COVID-19
On Oct. 20, 2020, the NIH announced that the researchers had completed the Adaptive COVID-19 Treatment Trial (ACTT-1),…
-
PerkinElmer immunoassay identiied therapeutic compounds capable of disrupting the SARS-CoV-2 spike protein/ACE2 interaction
On Oct. 20, 2020, PerkinElmer announced that a research team at the National Center for Advancing Translational Sciences…
-
BioMedomics’ COVID-19 IgM/IgG Rapid Test approved by INVIMA in Colombia
On Oct. 20, 2020, BioMedomics announced that the National Institute for Food and Drug Surveillance (INVIMA) had provided…
-
European Investment Bank provided Immunic with ﾀ245 million to support development of COVID-19 therapy
On Oct. 20, 2020, the European Investment Bank (EIB) and Immunic announced the signing of a ﾀ24.5 million…
-
Study discovered gene that helps us know when itﾒs time to urinate
On Oct. 19, 2020, researchers annoounced they had discovered that a gene, called PIEZO2, may be responsible for…
-
Bio-Techne announced commercial release of SARS-CoV-2 multi-antigen serology assay kit for simple western
On Oct. 19, 2020, Bio-Techne announced that ProteinSimple, a Bio-Techne brand, released its SARS-CoV-2 Multi-Antigen Serology Module for…
-
LabCorp and Swedish extended laboratory services relationship providing access to COVID-19 testing and diagnostics
On Oct. 19, 2020, LabCorp and Swedish, the largest nonprofit healthcare system in the Puget Sound region, announced…
-
LabCorp launched quantitative antibody test to assess effectiveness ef COVID-19 vaccines in clinical trials
On Oct. 19, 2020, LabCorp announced a test that provided a quantitative measurement of an individualﾒs SARS-CoV-2 IgG…
-
Atossa Therapeutics completed enrollment of phase 1 clinical study of AT-301 Coronavirus nasal spray
On Oct. 19, 2020, Atossa Therapeutics announced it had completed enrollment in its Phase 1 clinical study using…
-
NIH began large clinical trial to test immune modulators for treatment of COVID-19
On Oct. 16, 2020, the NIH launched an adaptive Phase 3 clinical trial to evaluate the safety and…
-
4D Nucleome Program Projects launched to map the nucleus, the information center of our cells
On Oct. 15, 2020 research teams from two divisions of the Allen Institute, the Allen Institute for Cell…
-
Entos announced spin-off company Aegis Life to support global vaccine commercialization
On Oct. 15, 2020, Entos Pharmaceuticals announces that its San Diego-based spinout company Aegis Life, will pursuing U.S….
-
FDA authorized phase 1 trial of ImmunityBioﾒs novel COVID-19 vaccine candidate hAd5 to drive T cell and antibody immunity
On Oct. 15, 2020, ImmunityBio announced it had received authorization from the FDA to begin a Phase I…
-
Ionis antisense medicine evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
On Oct. 15, 2020, Ionis Pharmaceuticals announced that IONIS-PKK-LRx was being evaluated in an investigator-initiated Phase 2 clinical…
-
Brazilian Health Regulatory Agency authorized Sorrento’s phase 2 clinical trial of Abivertinib in COVID-19 patients
On Oct. 14, 2020, Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed…
-
WHO announced position on genetically modified mosquitoes
On Oct. 14, 2020, recognizing the urgent need for new tools to combat vector-borne diseases (VBDs), and in…
-
US DOD expanded collaboration with AstraZeneca to develop and manufacture an investigational mab to prevent COVID-19
On Oct. 14, 2020, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD)…
-
Vaxart announced positive hamster challenge study data for its oral COVID-19 vaccine
On Oct. 14, 2020, Vaxart announced that the FDA had completed its review of the Companyﾒs Investigational New…
-
Thermo Fisher announced plans to expand sterile filling capacity for therapies and vaccines with new facility in Singapore
On Oct. 14, 2020, Thermo Fisher Scientific announced plans to develop two new sterile filling lines in Singapore…
-
Tevogen Bio submitted IND for T cell treatment in COVID-19
On Oct. 14, 2020, Tevogen Bio announced that its Investigational New Drug (IND) application to develop a COVID-19…
-
Roche launched laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
On Oct. 13, 2020, Roche announced that it intended to launch a high-volume SARS-CoV-2 Antigen test as an…
-
NIH study to identify promising COVID-19 treatments for larger clinical trials
On Oct. 13, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), launched a study designed to…
-
NeoGenomics expanded global footprint in pharma services with new clinical research laboratory in Suzhou, China
On Oct. 13, 2020, NeoGenomics announced plans to open a state-of-the-art research laboratory in China in association with…
-
Apogenix advanced clinical development of CD95L inhibitor asunercept in European COVID-19 phase II trial
On Oct. 13, 2020, Apogenix announced that the first patient has been enrolled in the ASUNCTIS trial. The…
